Detalhe da pesquisa
1.
Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation.
Blood
; 141(9): 1047-1059, 2023 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455198
2.
Data mining analysis of the PP2A cell cycle axis in mesothelioma patients.
J Cell Physiol
; 235(6): 5284-5292, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31858592
3.
GATA2 germline mutations impair GATA2 transcription, causing haploinsufficiency: functional analysis of the p.Arg396Gln mutation.
J Immunol
; 194(5): 2190-8, 2015 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25624456
4.
Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.
Nat Genet
; 39(5): 593-5, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17435759
5.
Regulation and role of the PP2A-B56 holoenzyme family in cancer.
Biochim Biophys Acta Rev Cancer
; 1878(5): 188953, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37437699
6.
Set Protein Is Involved in FLT3 Membrane Trafficking.
Cancers (Basel)
; 15(8)2023 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37190162
7.
SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia.
Blood
; 115(3): 615-25, 2010 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-19965692
8.
Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
Haematologica
; 97(4): 543-50, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22133779
9.
Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.
Haematologica
; 96(10): 1448-56, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21750091
10.
Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death.
Cancer Discov
; 11(5): 1268-1285, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355179
11.
Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice.
J Clin Invest
; 117(12): 3696-707, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18037989
12.
CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia.
Haematologica
; 100(5): e183-5, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25637054
13.
The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias.
Cells
; 9(3)2020 02 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32110991
14.
A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.
Cancer Lett
; 468: 1-13, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31593801
15.
A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia.
Blood Cancer J
; 10(1): 3, 2020 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31913266
16.
Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".
Sci Transl Med
; 11(501)2019 07 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31316003
17.
Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells.
Haematologica
; 98(9): e103-4, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23812941
18.
In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
Haematologica
; 93(4): 533-42, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18322257
19.
Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia.
Proc Natl Acad Sci U S A
; 107(44): E167-8; author reply E169-70, 2010 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-20930122
20.
Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib.
Oncotarget
; 9(47): 28474-28485, 2018 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29983874